NEW YORK, March 26, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MetLife, Inc. (NYSE:MET) between February 27, 2013 and January 29, 2018, both dates inclusive (“Class Period”) of the April 6, 2018 lead plaintiff deadline in the first filed class action commenced by the Rosen Law Firm. The lawsuit seeks to recover damages for MetLife investors under the federal securities laws.
To join the MetLife class action, go to http://www.rosenlegal.com/cases-1279.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) MetLife’s practices and procedures used to estimate its reserves set aside for annuity and pension payments were inadequate; (2) MetLife had inadequate internal controls over financial reporting; and (3) as a result, defendants’ statements about MetLife’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1279.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Jetstar to Charge for Overhead Cabin Bags From February
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



